Literature DB >> 35766692

Polymorphisms rs2010963 and rs833061 of the VEGF gene in polycystic ovary syndrome.

Anna Luiza Silva Almeida Vicente1, Alessandra Bernadete Trovó de Marqui2, Mariana Kefalas Oliveira Gomes2, Alan Vinicius Assunção-Luiz3, Marly Aparecida Spadotto Balarin2, Sarah Cristina Sato Vaz Tanaka2, Elisabete Aparecida Mantovani Rodrigues de Resende2, Marco Fábio Prata Lima2, Mariangela Torreglosa Ruiz Cintra2.   

Abstract

OBJECTIVE: The polycystic ovary syndrome is the most common endocrine disorder, characterized by the dysregulation of ovarian angiogenesis. This alteration can be related to changes in the activities of the vascular endothelial growth factor (VEGF) gene. Single-nucleotide polymorphisms have been observed in the promoter, intronic, and untranslated regions of the VEGF gene, and several studies have suggested that these polymorphisms may be associated with the risk of polycystic ovary syndrome. This study aimed to investigate the association between rs2010963 and rs833061 polymorphisms and haplotypes of VEGF in the etiology of polycystic ovary syndrome.
METHODS: A total of 210 women, 102 diagnosed with polycystic ovary syndrome and 108 controls, participated in this study. The genotyping of the samples was performed by PCR-RFLP and real-time PCR for rs2010963 and rs833061 polymorphisms, respectively. The statistical analyses were performed by the chi-square test and logistic regression model.
RESULTS: The clinical characteristics of the patients showed that 75.8% of the patients did not become pregnant, 36.3% had a family history of polycystic ovary syndrome, 58.6% were obese, and about 60% had clinical characteristics of hyperandrogenism. There were no associations between the distribution of rs2010963 (OR 1.24; 95%CI 0.60-2.57; p=0.56) and rs833061 (OR 0.78; 95%CI 0.32-1.92; p=0.59) in patients and controls.
CONCLUSIONS: The patients with polycystic ovary syndrome have similar rates of VEGF polymorphisms rs2010963 and rs833061 on the general population.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35766692      PMCID: PMC9575905          DOI: 10.1590/1806-9282.20211345

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.712


  24 in total

1.  Polycystic ovary syndrome: controversies and challenges.

Authors:  José Maria Soares Júnior; Maria Cândida P Baracat; Gustavo Arantes Rosa Maciel; Edmund Chada Baracat
Journal:  Rev Assoc Med Bras (1992)       Date:  2015 Nov-Dec       Impact factor: 1.209

2.  The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study.

Authors:  Ana Lúcia Beltrame; Paulo Serafini; Eduardo L A Motta; José Maria Soares Júnior; Edmund C Baracat
Journal:  Gynecol Endocrinol       Date:  2012-11-20       Impact factor: 2.260

3.  Association between Vascular Endothelial Growth Factor Gene Polymorphisms and Pre-Eclampsia Susceptibility: An Updated Meta-Analysis.

Authors:  Xiaoyi Wang; Tao Sun; Guochang Chen; Hong Gao
Journal:  Immunol Invest       Date:  2019-08-28       Impact factor: 3.657

4.  Effects of melatonin on histomorphology and on the expression of steroid receptors, VEGF, and PCNA in ovaries of pinealectomized female rats.

Authors:  Lucrecia Regina G Romeu; Eduardo Leme A da Motta; Carla C Maganhin; Celina T F Oshima; Marcelle C Fonseca; Karina F Barrueco; Ricardo S Simões; Renata Pellegrino; Edmund C Baracat; José M Soares-Junior
Journal:  Fertil Steril       Date:  2010-06-03       Impact factor: 7.329

5.  Vascular endothelial growth factor (-460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population.

Authors:  Belkis Henidi; Wajih Kaabachi; Abir Naouali; Safa Kaabachi; Amel Zhioua; Faycal Haj Sassi; Kamel Hamzaoui
Journal:  Syst Biol Reprod Med       Date:  2015-05-18       Impact factor: 3.061

6.  Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome.

Authors:  Pervin Vural; Zeynep Küskü-Kiraz; Semra Doğru-Abbasoğlu; Esra Cil; Berrin Karadağ; Cemil Akgül; Müjdat Uysal
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-07-23       Impact factor: 2.435

7.  The VEGF +405 G>C 5' untranslated region polymorphism and risk of PCOS: a study in the South Indian Women.

Authors:  Praveen Guruvaiah; Suresh Govatati; Tumu Venkat Reddy; Dakshayani Lomada; Mamata Deenadayal; Sisinthy Shivaji; Manjula Bhanoori
Journal:  J Assist Reprod Genet       Date:  2014-08-09       Impact factor: 3.412

Review 8.  Association between vascular endothelial growth factor gene polymorphisms and PCOS risk: a meta-analysis.

Authors:  Yuxi Li; Lanlan Fang; Yiping Yu; Hao Shi; Sijia Wang; Yiran Li; Yujia Ma; Yang Yan; Ying-Pu Sun
Journal:  Reprod Biomed Online       Date:  2019-12-24       Impact factor: 3.828

9.  Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population.

Authors:  Assila Ben Salem; Fatma Megdich; Olfa Kacem; Malek Souayeh; Faten Hachani Ben Ali; Sondes Hizem; Faouzi Janhai; Mounir Ajina; Muhammad Abu-Elmagd; Mourad Assidi; Mohammed H Al Qahtani; Touhami Mahjoub
Journal:  BMC Genomics       Date:  2016-10-17       Impact factor: 3.969

10.  Metformin improves ovarian follicle dynamics by reducing theca cell proliferation and CYP-17 expression in an androgenized rat model.

Authors:  Roberta Rassi Mahamed; Carla Cristina Maganhin; Gisela Rodrigues Silva Sasso; Manuel de Jesus Simões; Maria Candida Pinheiro Baracat; Edmund Chada Baracat; José Maria Soares-
Journal:  J Ovarian Res       Date:  2018-03-01       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.